Myelodysplastic neoplasms: An overview on diagnosis, risk-stratification, molecular pathogenesis, and treatment - 15/11/22
, Adriano de Paula Sabino b, ⁎ Abstract |
Myelodysplastic neoplasms are clonal hematological malignancies arising from hematopoietic stem cells that accumulate various mutations. MDS is heterogeneous in nature but uniformly characterized by ineffective hematopoiesis, dysplasia of one or more cell lineages, and an increased risk of transformation to acute myeloid leukemia. Disease-related risk is commonly assessed using the Revised International Prognostic Scoring System based on five cytogenetic risk groups, together with refined categories for bone marrow blast percentage and number of cytopenias. Therapeutic options for patients with MDS vary from supportive care to allogeneic stem cell transplantation depending on the disease and patient-related risk factors. Despite great progress in understanding the molecular mechanisms underlying MDS, this knowledge has not yet been translated into the approval of a curative treatment.
Le texte complet de cet article est disponible en PDF.Graphical Abstract |
Highlights |
• | Myelodysplastic neoplasms are characterized by ineffective hematopoiesis. |
• | Classification is defined by morphological features and genetic abnormalities. |
• | Prognosis is best defined by the Revised International Prognostic Scoring System. |
• | More than 80% of patients carry one or more somatic mutations. |
• | The only potential curative therapy is hematopoietic stem cell transplantation. |
Abbreviations : allo-HCT, AML, ASXL1, AZA, BCL-2, bi, BM, CCUS, CHIP, cnLOH, DDX41, DEC, DNMT3A, EPO, ESA, ETV6, EZH2, f, FLT3, GATA2, HDAC, HIF, h, HMA, HSC, IB, ICUS, IDH1, IDH2, IDUS, IPSS, IPSS-M, IPSS-R, IST, ITIH3, JAK2, KMT2A, LB, MDS, MLL, NGS, PB, pCT, PPM1D, PTD, RAS, ROBO1, RS, RUNX1, SCT, SF, SF3B1, SAMD9, SAMD9L, SRSF2, TET2, TGF-β, TP53, TPO, U2AF1, VAF, WHO, WPSS, ZRSR2
Keywords : Myelodysplastic neoplasms, Diagnosis, Cytogenetic, Genomic, Risk stratification, Treatment
Plan
Vol 156
Article 113905- décembre 2022 Retour au numéro
Article précédent
- Cancer stem cells in immunoregulation and bypassing anti-checkpoint therapy
- Elnaz Rouzbahani, Jamal Majidpoor, Sajad Najafi, Keywan Mortezaee
- A Chinese classical prescription Qianjinweijing Decoction in treatment of lung cancer: An overview
- PeiYu Liu, QingYang Zhao, Yang Xu, JiaXue Ye, JingRui Tan, Jie Hou, YaZhuo Wang, JianWei Li, WeiZhen Cui, ShiYuan Wang, XueZhen Wang
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?